Dividend Assets Capital LLC Decreases Stake in Amgen Inc. $AMGN

Dividend Assets Capital LLC cut its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 20.1% during the first quarter, HoldingsChannel.com reports. The fund owned 35,864 shares of the medical research company’s stock after selling 9,002 shares during the period. Amgen accounts for about 2.5% of Dividend Assets Capital LLC’s holdings, making the stock its 11th largest holding. Dividend Assets Capital LLC’s holdings in Amgen were worth $12,619,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of AMGN. Vanguard Group Inc. increased its holdings in shares of Amgen by 1.8% in the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after purchasing an additional 961,975 shares during the last quarter. State Street Corp boosted its stake in Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after buying an additional 1,287,310 shares during the last quarter. Capital World Investors grew its holdings in Amgen by 22.9% in the 4th quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock valued at $7,560,249,000 after buying an additional 4,302,237 shares in the last quarter. Capital International Investors increased its stake in shares of Amgen by 1.5% in the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company’s stock worth $5,414,296,000 after acquiring an additional 282,219 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Amgen by 7.8% during the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president directly owned 7,009 shares in the company, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.85% of the stock is owned by company insiders.

Amgen Price Performance

Shares of AMGN opened at $374.15 on Monday. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $391.29. The stock has a market cap of $201.93 billion, a PE ratio of 26.04, a P/E/G ratio of 3.68 and a beta of 0.41. The firm has a 50-day simple moving average of $342.43 and a two-hundred day simple moving average of $348.09. The company has a debt-to-equity ratio of 5.65, a current ratio of 1.26 and a quick ratio of 1.01.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The business’s revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, analysts forecast that Amgen Inc. will post 22.39 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on AMGN shares. Erste Group Bank reissued a “hold” rating on shares of Amgen in a research report on Tuesday, May 5th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research note on Thursday, June 18th. Jefferies Financial Group started coverage on shares of Amgen in a research note on Tuesday, March 10th. They issued a “hold” rating and a $350.00 price target for the company. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Finally, Wells Fargo & Company upped their price objective on Amgen from $375.00 to $390.00 and gave the company an “equal weight” rating in a report on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $355.50.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.